Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research led by Department of Physiology, Anatomy & Genetics researcher Dr Kerstin Timm shows that a recently developed imaging technique can detect early metabolic changes in the heart caused by a commonly used chemotherapy drug, which is known to increase risk of heart failure in cancer survivors.

Illustration of a human heart

Chemotherapy has greatly improved cancer survival rates, especially in breast cancer patients. However, some chemotherapeutic drugs such as doxorubicin have side effects on the heart, and 5-10% of cancer survivors develop heart failure as a consequence of their cancer treatment. Unfortunately, it is not currently possible to predict which patient will suffer long-term heart problems due to their cancer therapy.

An imaging tool to screen patients regularly to check for early signs of toxicity on the heart is therefore desirable to detect any changes early and intervene with appropriate treatment. However, current clinical imaging is limited to detection of cardiac dysfunction, not prior toxic events. A recently developed imaging technique called “Hyperpolarized 13C Magnetic Resonance Imaging” allows us to assess real-time metabolic fluxes in vivo, and may therefore provide the ability to detect changes in mitochondrial metabolism and function in the doxorubicin treated heart. This technique has been pioneered in the UK in both the rodent and human heart by Professor Damian Tyler’s lab.  

The full story is available on the Department of Physiology, Anatomy & Genetics website

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Regular meat consumption linked with a wide range of common diseases

Research

Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.